RxDoctor Payments Data

Carlos Chang, MD

Internal Medicine · Tavares, FLNPI 1922005016

Payments from drug & device makers

$798in general payments, 2019–2025

Across 14 payments — averaging $57.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$203
  • Pfizer$165
  • Amgen$100
  • Gilead$99
  • Johnson & Johnson$98
  • Medtronic$56
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$483,348
Medicare patients
785
Services billed
6,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$145,464
JardianceEmpagliflozin100$88,818
OzempicSemaglutide45$40,128
MounjaroTirzepatide28$36,318
JanuviaSitagliptin Phosphate33$27,121
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$21,286
XareltoRivaroxaban44$17,682
BrilintaTicagrelor28$16,663
FarxigaDapagliflozin Propanediol18$14,925
Bydureon BciseExenatide Microspheres13$10,034
MyrbetriqMirabegron14$7,222
Atorvastatin Calcium652$6,778
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$5,126
Levothyroxine Sodium397$4,888
Memantine Hcl81$4,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$145,464172 claims
Novo NordiskOzempic$203$40,12845 claims
Lilly USA, LLCMounjaro$23$36,31828 claims
Johnson & JohnsonXarelto$98$17,68244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tavares

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →